We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$2.21M
Cap. Flow
-$39.8M
Cap. Flow %
-1.28%
Top 10 Hldgs %
35.29%
Holding
188
New
16
Increased
26
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.7M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$32.2M
3
MRNA icon
Moderna
MRNA
+$25.5M
4
DHR icon
Danaher
DHR
+$16.7M
5
RMD icon
ResMed
RMD
+$15.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.3M
2
EXAS
Exact Sciences
EXAS
+$21.5M
3
CTLT
CATALENT, INC.
CTLT
+$19.2M
4
XRAY icon
Dentsply Sirona
XRAY
+$17.1M
5
CI icon
Cigna
CI
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Real Estate 2.82%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
176
Stoke Therapeutics
STOK
$1.81B
– –
-99,263
Closed -$2.52M
STVN icon
177
Stevanato
STVN
$5.51B
– –
-137,872
Closed -$3.49M
TECH icon
178
Bio-Techne
TECH
$11.2B
– –
-21,600
Closed -$2.62M
VIR icon
179
Vir Biotechnology
VIR
$1.47B
– –
-81,400
Closed -$3.54M
WST icon
180
West Pharmaceutical
WST
$24.4B
– –
-6,240
Closed -$2.65M
XENE icon
181
Xenon Pharmaceuticals
XENE
$5.98B
– –
-169,030
Closed -$2.58M
CTLT
182
DELISTED
CATALENT, INC.
CTLT
– –
-143,913
Closed -$19.2M
GMDA
183
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-118,142
Closed -$463K
BCEL
184
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-229,372
Closed -$1.43M
TCRR
185
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-235,808
Closed -$2.01M
TPTX
186
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-119,324
Closed -$7.93M
4 5 6 7
8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Tekla Capital Management held 188 positions worth $3.11B, up 0.07% from $3.11B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q4 2021 filing shows 16 new, 26 increased, 40 reduced and 17 closed positions. Its largest new stake was AMN Healthcare: 61,201 shares worth $7.49M. The largest sale was Biogen, an estimated $25.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2021 buy was AMN Healthcare: 61,201 shares worth $7.49M.
  • Tekla Capital Management added most to Pfizer in Q4 2021, an estimated $35.7M increase.
  • Tekla Capital Management's biggest Q4 2021 reduction was Biogen, cutting an estimated $25.3M.
  • Tekla Capital Management fully exited Exact Sciences in Q4 2021, selling an estimated $21.5M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $3.11B portfolio in Q4 2021.
  • Tekla Capital Management opened 16 new positions and closed 17 in Q4 2021.
  • Tekla Capital Management's portfolio value rose 0.07% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.